Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.
説明 | Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease. |
ターゲット&IC50 | AhR:13 nM(EC50) |
In vitro | Tapinarof activates the AhR pathway through direct binding. Tapinarof induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) in a dose-dependent way. |
In vivo | Tapinarof mediates its anti-inflammatory effects via the AhR pathway in IMQ-treated mice. In mice expressing AhR on a C57Bl/6 background, both Tapinarof and 6-formylindolo(3,2-b)carbazole (FICZ) significantly lower clinical inflammation scores. Conversely, AhR knockout (KO) mice exhibit no such anti-inflammatory response to Tapinarof. FICZ serves as a benchmark in these experiments, demonstrating comparable reduction in inflammation in wild-type mice, but ineffective in AhR KO mice. |
別名 | GSK2894512, Benvitimod, WBI 1001 |
分子量 | 254.32 |
分子式 | C17H18O2 |
CAS No. | 79338-84-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (216.26 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tapinarof 79338-84-4 Immunology/Inflammation Metabolism AhR Aryl Hydrocarbon Receptor Inhibitor WBI1001 GSK2894512 inhibit WBI-1001 GSK 2894512 GSK-2894512 Benvitimod WBI 1001 inhibitor